Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICoN-1 clofazimine inhalation add-on study in pulmonary MAC infection
jRCT2021240037Phase 3Completed
- Sponsor
- MannKind
- Start
- Feb 2025
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial of MNKD-101 and Placebo-COD Research Private Ltd in Pulmonary mycobacteriosis (3 arms), sponsored by MannKind. Primary endpoints: Sputum culture conversion by end of Month 6 and Long-term safety profile. Started Feb 2025; status: completed.
02
Drugs
MNKD-101Placebo-COD Research Private Ltd
03
Conditions
Pulmonary mycobacteriosis
Beyond the preview
Go deeper on jRCT2021240037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240037.